Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1% - Full Text View

Home Search Study Topics Glossary

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

This study has been completed.

Sponsored by:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00377546

Purpose

To compare the penetration of three different NSAIDs.

Condition	Intervention	Phase
Vitrectomy	Drug: Nepafenac Drug: Ketorolac LS, Bromfenac	Phase IV

Drug Information available for: Ketorolac Ketorolac tromethamine Bromfenac Bromfenac sodium Nepafenac

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Active Control, Parallel Assignment

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00377546

Locations

United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

Jeffrey Heier, MD

Ophthalmic Consultants of Boston

More Information

Study ID Numbers:	5264
Study First Received:	September 14, 2006
Last Updated:	September 23, 2008
ClinicalTrials.gov Identifier:	NCT00377546
Health Authority:	United States: Institutional Review Board

Keywords provided by Innovative Medical:

Retinal Surgery

Study placed in the following topic categories:

Bromfenac
Ketorolac
Ketorolac Tromethamine

ClinicalTrials.gov processed this record on January 15, 2009